about
Enhanced efficacy of liposome-encapsulated ribavirin against Rift Valley fever virus infection in miceToxicologic effects of ribavirin in cats.Antileishmanial activities of stearylamine-bearing liposomesThe use of liposomally-entrapped gentamicin in the treatment of bovine Staphylococcus aureus mastitisToxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B.Interleukin-1beta (IL-1beta) inhibition: a possible mechanism for the anti-inflammatory potency of liposomally conjugated methotrexate formulations in arthritis.Liposome encapsulation of clofazimine reduces toxicity in vitro and in vivo and improves therapeutic efficacy in the beige mouse model of disseminated Mycobacterium avium-M. intracellulare complex infection.Therapeutic efficacy of liposomal clofazimine against Mycobacterium avium complex in mice depends on size of initial inoculum and duration of infection.Successful treatment using gentamicin liposomes of Salmonella dublin infections in mice.Activity against rhinoviruses, toxicity, and delivery in aerosol of enviroxime in liposomes.Liposome-incorporated ciprofloxacin in treatment of murine salmonellosis.Beyond oncology--application of HPMA copolymers in non-cancerous diseases.New delivery strategies for the old pentavalent antimonial drugs.In vitro study of the anti-leishmanial activity of biodegradable nanoparticles.Biodegradable microspheres: polyacryl starch microparticles as a delivery system for the antileishmanial drug, sodium stibogluconate.Imaging the pharmacology of nanomaterials by intravital microscopy: Toward understanding their biological behavior.Antimonial drugs entrapped into phosphatidylserine liposomes: physicochemical evaluation and antileishmanial activity.Nanostructured delivery systems with improved leishmanicidal activity: a critical review.Differential inhibition of macrophage microbicidal activity by liposomes.Stavudine-loaded mannosylated liposomes: in-vitro anti-HIV-I activity, tissue distribution and pharmacokinetics.Liposomes as carriers of peptide antigens: induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides.Preparation and characterization of niosomes containing ribavirin for liver targeting.Development of liposomes loaded with anti-leishmanial drugs for the treatment of cutaneous leishmaniasis.Liposome uptake by human retinal pigment epithelial cells in culture.Intrapulmonary deposition of aerosolized Evans blue dye and liposomes in an experimental porcine model of early ARDS.
P2860
Q27478096-DA7A5923-D9D0-4B34-BD00-6C1856C15DE8Q33493051-837C2B0C-C280-4A74-9A77-425F1FC0E3F7Q33979887-A1700010-3B77-433E-83D6-9A0087DF7527Q34080919-735A84E8-2E72-43D9-BFA7-FCC17D8DE88EQ34230457-792BC9E6-2842-46BA-AB3A-3388DC77FA2EQ35041474-6F90466B-0900-49AD-A986-D7E90035FF14Q35126170-80CACDCA-EA8D-47FC-8F11-878EAE4E2924Q35130708-28AC271C-557D-47BB-90E7-E363AABE4F97Q35248762-3210D30E-9EC3-4FF6-8ED8-87D3C04B3C57Q35309733-5B48033B-9166-41D3-9CC7-0B882131B292Q35899686-AF8E793B-3CBA-42B6-ABF8-D233721615C6Q37631869-32D46EFD-64F3-42BE-A89A-FE92A03EBC82Q37804399-51B3F551-DCFB-477A-B466-40DE9A675940Q38574040-AE978C41-7838-439E-9E10-8227A30966A5Q38596856-D8727FF6-B360-4D98-B8D2-1232724DE5DBQ38856246-11A57E22-2BB8-4AAD-BC52-DFE2A9C5EF40Q38914848-E577A3D4-69E5-458D-BAF0-F5FDA157E44BQ40099567-D37A12A9-8E1C-4B78-ABED-B3AD41FE3428Q40176503-655EBAF5-E1D4-4B2A-A2CD-238722BC7287Q40287352-13A0DC58-E3D0-47E1-8982-02DA316DE6B7Q40433315-8E247E9D-ACAD-4D3A-8D50-F2F890C86D5BQ43115879-BD03A308-B0EE-47DF-B89A-9A4F91049C5AQ44058897-37F76618-9701-4BF8-93EB-C8FA738DB113Q50526336-DC3AFAE6-29C4-4AC9-B583-02C9F07FE1C3Q50883946-5032F125-7056-4442-98A6-1802C0BE56EE
P2860
description
1983 nî lūn-bûn
@nan
1983年の論文
@ja
1983年論文
@yue
1983年論文
@zh-hant
1983年論文
@zh-hk
1983年論文
@zh-mo
1983年論文
@zh-tw
1983年论文
@wuu
1983年论文
@zh
1983年论文
@zh-cn
name
Delivery of liposome-encapsulated drugs to macrophages.
@en
type
label
Delivery of liposome-encapsulated drugs to macrophages.
@en
prefLabel
Delivery of liposome-encapsulated drugs to macrophages.
@en
P1476
Delivery of liposome-encapsulated drugs to macrophages.
@en
P2093
P304
P356
10.1016/0163-7258(83)90010-4
P577
1983-01-01T00:00:00Z